New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care
Go back to New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care| Abbott Laboratories (NYSE: ABT) | Delayed: 88.18 -1.47 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $89.65 | 52 Week High | $46.38 | |||
| Open | $89.62 | 52 Week Low | $36.00 | |||
| Day High | $90.29 | P/E | 58.79 | |||
| Day Low | $87.07 | EPS | $1.50 | |||
| Volume | 13,786,283 | |||||
